This manuscript explores the dynamic behaviors of Pol II and Pol III puncta that encompass the SL1 and 5S genes, following up on the authors' prior studies on ATTF-6. The authors show that ATTF-6 is ...

Company leaders to engage the global research community on circular RNA, AI-driven therapeutics, and next-generation RNA platforms HOUSTON, TX, UNITED STATES, March ...

High-Altitude-Long-Endurance (HALE) Unmanned Aerial Vehicles (UAV) operating at low Reynolds numbers face significant challenges from atmospheric gusts, which can intensify flow separation and induce ...

CREATE Medicines ("CREATE") broadens clinical programs and capabilities to expand therapeutic potential and improve patient outcomes Therapies tolerably program immune cells inside the human body, ...

Duchenne therapy may be evolving from slowing disease to reversing it—with RNA approaches offering the prospect of restoring function. Ongoing research will determine if these advances can deliver ...

Not revised: This Reviewed Preprint includes the authors’ original preprint (without revision), an eLife assessment, and public reviews. The manuscript by Xu et al. reported base-resolution mapping of ...

Novo Nordisk is looking to add to its obesity pipeline, teaming up with California biotech Replicate Bioscience to design and develop an RNA-based treatment for obesity and diabetes. The partners did ...

A few years after it was founded with the aim of taking RNA therapies to the next level, Arnatar Therapeutics Inc. emerged from stealth, disclosing a $52 million series A round raised in 2024 as well ...

The buy-side continues to face challenges in appropriately bucketing orders based on their alpha profiles and characteristics such as volatility, spread, and liquidity. Traditionally, algo wheels ...

Survival outcomes in locally advanced inoperable NSCLC patients converted to resectable disease by neoadjuvant therapy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...